Search Results - "FDA"

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database by Ruixue Liu, Chunxiao Liu, Dianwei Feng, Tongxin Guo, Ying Wang

Connect to this object online.

THE FDA HAS APPROVED TWO GENE THERAPY DRUGS FOR THE TREATMENT OF SICKLE CELL ANEMIA by article Editorial

Connect to this object online.

Inside the FDA - The business and politics behind the drugs we take and the food we eat by Eliezer J. Barreiro

Connect to this object online.

Should the FDA's criteria for the clinical efficacy of cachexia drugs be changed? Is Ostarine safe and effective? by Charles Paul Lambert

Connect to this object online.

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor by Shanada Monestime, Dovena Lazaridis

Connect to this object online.

Pembrolizumab-Associated Cardiotoxicity: A Retrospective Analysis of the FDA Adverse Events Reporting System by Stefan Milutinovic, Predrag Jancic, Vera Jokic, Marija Petrovic, Igor Dumic, Ambar Morales Rodriguez, Nikola Tanasijevic, Dustin Begosh-Mayne, Dragana Stanojevic, Ricardo O. Escarcega, Juan Lopez-Mattei, Xiangkun Cao

Connect to this object online.

Level of Evidence Associated with FDA Safety Communications with Drug Labeling Changes: 2010-2014 by Benjamin Hixon, Joseph M. Lowrey, Lindsay N Hume, Katelynn Mayberry, Maisha Kelly Freeman

Connect to this object online.

Consideration of nutrition and sustainability in public definitions of 'healthy' food: an analysis of submissions to the US FDA by Emily H Belarmino, Michelle Carfagno, Lauren Kam, Kene-Chukwu Ifeagwu, Miriam E Nelson, Rebecca A Seguin-Fowler

Connect to this object online.

The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine by Qian Wang, Jianlin Han, Alexander Sorochinsky, Aitor Landa, Greg Butler, Vadim A. Soloshonok

Connect to this object online.

FOR THE FIRST TIME, THE FDA HAS APPROVED A GEL FOR THE TREATMENT OF MOLLUSCUM CONTAGIOSUM AT HOME by article Editorial

Connect to this object online.

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor by Yunyan Pan, Yunyan Pan, Yu Wang, Yu Wang, Yifan Zheng, Yifan Zheng, Jie Chen, Jia Li

Connect to this object online.

FDA HAS APPROVED NEW TREATMENT FOR CHILDREN WITH ANY HEPATITIS C VIRUS STRAINS

Connect to this object online.

Repurposing FDA Drug Compounds against Breast Cancer by Targeting EGFR/HER2 by Irving Balbuena-Rebolledo, Itzia Irene Padilla-Martínez, Martha Cecilia Rosales-Hernández, Martiniano Bello

Connect to this object online.

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer's Drugs by Débora Nunes, Joana A. Loureiro, Maria Carmo Pereira

Connect to this object online.

A network of regulatory innovations to improve FDA quality assessments of human drug applications by Russie Tran, Grace Fraser, Adam C. Fisher, Sau L. Lee, Ashley Boam, Stelios Tsinontides, Jennifer Maguire, Lawrence X. Yu, Susan Rosencrance, Steven Kozlowski, Don Henry

Connect to this object online.

FDA approval of Pfizer-BioNTech: Evaluating the significance of mRNA vaccine approval by Syed Abdullah Monawwer, Raahim Naeem

Connect to this object online.

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis by Robert Roskoski, Jr

Connect to this object online.

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases by Annie Mayence, Jean Jacques Vanden Eynde

Connect to this object online.

Rule of five violations among the FDA-approved small molecule protein kinase inhibitors by Robert Roskoski, Jr

Connect to this object online.

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS) by Ming-Tao Wen, Jia-Cheng Li, Jia-Cheng Li, Bo-Wen Lu, Hua-Rong Shao, Pei-Xue Ling, Fei Liu, Fei Liu, Gang Li, Gang Li, Di Luo, Di Luo

Connect to this object online.